Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 22:9:28.
doi: 10.12703/r/9-28. eCollection 2020.

An overview of the treatment of cutaneous leishmaniasis

Talissa F Garza-Tovar  1 , Marco I Sacriste-Hernández  1 , Eder R Juárez-Durán  2 , Roberto Arenas  2
Affiliations
Review

An overview of the treatment of cutaneous leishmaniasis

Talissa F Garza-Tovar et al. Fac Rev. .

Abstract

Leishmaniasis is a neglected tropical disease caused by species of Leishmania, with a broad spectrum of clinical manifestations, such as cutaneous, visceral, and mucocutaneous presentations. Many drugs are used for its treatment, and a current effective one is a pentavalent antimonial, especially in developing countries. In this review, we discuss recent proposed therapies as well as their side effects.

Keywords: Antimonials; Leishmaniasis; Treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.No competing interests were disclosed.No competing interests were disclosed.

Figures

Figure 1.
Figure 1.. Cutaneous leishmaniasis in a Mexican patient.
Figure 2.
Figure 2.. After four doses of intralesional meglumine antimoniate.
See this image and copyright information in PMC

References

    1. Torres-Guerrero E, Quintanilla-Cedillo MR, Ruiz-Esmenjaud J, et al. : Leishmaniasis: a review [version 1; peer review: 2 approved]. F1000Res. 2017; 6: 750. 10.12688/f1000research.11120.1 - DOI - PMC - PubMed
    1. Wolf Nassif P, de Mello TFP, Navasconi TR, et al. : Safety and efficacy of current alternatives in the topical treatment of cutaneous leishmaniasis: a systematic review. Parasitology. 2017; 144(8): 995–1004. 10.1017/S0031182017000385 - DOI - PubMed
    1. Aronson NE, Joya CA: Cutaneous Leishmaniasis: Updates in Diagnosis and Management. Infect Dis Clin North Am. 2019; 33(1): 101–17. 10.1016/j.idc.2018.10.004 - DOI - PubMed
    1. Uribe-Restrepo AF, Prieto MD, Cossio A, et al. : Eligibility for Local Therapies in Adolescents and Adults with Cutaneous Leishmaniasis from Southwestern Colombia: A Cross-Sectional Study. Am J Trop Med Hyg. 2019; 100(2): 306–10. 10.4269/ajtmh.18-0643 - DOI - PMC - PubMed
    1. Ramalho DB, da Silva RE, de Senna MCR, et al. : Meglumine antimoniate intralesional infiltration for localised cutaneous leishmaniasis: a single arm, open label, phase II clinical trial. Mem Inst Oswaldo Cruz. 2018; 113(9): e180200. 10.1590/0074-02760180200 - DOI - PMC - PubMed

LinkOut - more resources